A detailed history of Avantax Advisory Services, Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 6,307 shares of EXAS stock, worth $362,526. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,307
Previous 6,827 7.62%
Holding current value
$362,526
Previous $288,000 48.96%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$42.43 - $70.83 $22,063 - $36,831
-520 Reduced 7.62%
6,307 $429,000
Q2 2024

Aug 09, 2024

BUY
$41.33 - $74.26 $154,367 - $277,361
3,735 Added 120.8%
6,827 $288,000
Q1 2024

May 08, 2024

BUY
$56.27 - $73.77 $506 - $663
9 Added 0.29%
3,092 $213,000
Q4 2023

Feb 07, 2024

SELL
$59.06 - $75.72 $6,142 - $7,874
-104 Reduced 3.26%
3,083 $228,000
Q3 2023

Nov 07, 2023

SELL
$65.94 - $99.04 $41,805 - $62,791
-634 Reduced 16.59%
3,187 $217,000
Q2 2023

Aug 11, 2023

SELL
$62.68 - $95.05 $23,191 - $35,168
-370 Reduced 8.83%
3,821 $358,000
Q1 2023

Apr 28, 2023

BUY
$47.19 - $70.77 $197,773 - $296,597
4,191 New
4,191 $284,000
Q1 2022

Apr 27, 2022

SELL
$57.56 - $82.54 $151,267 - $216,915
-2,628 Closed
0 $0
Q4 2021

Jan 24, 2022

SELL
$72.5 - $100.68 $17,037 - $23,659
-235 Reduced 8.21%
2,628 $205,000
Q3 2021

Oct 21, 2021

SELL
$90.24 - $124.05 $10,197 - $14,017
-113 Reduced 3.8%
2,863 $275,000
Q2 2021

Jul 29, 2021

BUY
$93.66 - $139.27 $46,549 - $69,217
497 Added 20.05%
2,976 $369,000
Q1 2021

May 13, 2021

SELL
$116.57 - $155.01 $5,012 - $6,665
-43 Reduced 1.7%
2,479 $327,000
Q4 2020

Jan 22, 2021

BUY
$99.61 - $142.12 $24,006 - $34,250
241 Added 10.57%
2,522 $334,000
Q3 2020

Oct 14, 2020

BUY
$72.92 - $102.01 $166,330 - $232,684
2,281 New
2,281 $233,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.